Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Non-Current Deffered Revenue (2019 - 2025)

Korro Bio (KRRO) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $4.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Deffered Revenue fell 38.45% year-over-year to $4.8 million, compared with a TTM value of $4.8 million through Sep 2025, down 38.45%, and an annual FY2024 reading of $5.9 million, changed N/A over the prior year.
  • Non-Current Deffered Revenue was $4.8 million for Q3 2025 at Korro Bio, up from $4.5 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $7.8 million in Q3 2024 and bottomed at $4.5 million in Q2 2025.